75N91024C00073
Definitive Contract
Overview
Government Description
SBIR PHASE II, TOPIC 431: AUTOMATIC TREATMENT PLANNING OF CERVICAL CANCER HIGH-DOSE RATE BRACHYTHERPAY FOR LOW-RESOURCE SETTINGS.
Awardee
Awarding / Funding Agency
Place of Performance
Austin, TX 78726 United States
Pricing
Fixed Price
Set Aside
Small Business Set Aside - Total (SBA)
Extent Competed
Full And Open Competition After Exclusion Of Sources
Research Type
Small Business Innovation Research Program (SBIR) Phase II
Est. Average FTE
6
Related Opportunity
BAA 75N91023R00044
Veloxai was awarded
Definitive Contract 75N91024C00073 (75N910-24-C-00073)
worth up to $2,000,000
by National Cancer Institute
in September 2024.
The contract
has a duration of 2 years and
was awarded
with a Small Business Total set aside
with
NAICS 541715 and
PSC AN12
via direct negotiation acquisition procedures with 3 bids received.
Status
(Open)
Last Modified 8/26/24
Period of Performance
9/4/24
Start Date
9/3/26
Current End Date
9/3/26
Potential End Date
Obligations
$2.0M
Total Obligated
$2.0M
Current Award
$2.0M
Potential Award
Award Hierarchy
Definitive Contract
75N91024C00073
Subcontracts
Activity Timeline
People
Suggested agency contacts for 75N91024C00073
Competition
Number of Bidders
3
Solicitation Procedures
Negotiated Proposal/Quote
Evaluated Preference
None
Commercial Item Acquisition
Commercial Item Procedures Not Used
Simplified Procedures for Commercial Items
No
Other Categorizations
Subcontracting Plan
Plan Not Required
Cost Accounting Standards
Exempt
Business Size Determination
Small Business
Awardee UEI
L267GZS3JE28
Awardee CAGE
8DMU1
Agency Detail
Awarding Office
75N910 NIH NCI
Funding Office
75N910
Created By
hhsmnguyen1
Last Modified By
hhsmnguyen1
Approved By
hhslpark2
Legislative
Legislative Mandates
None Applicable
Performance District
TX-37
Senators
John Cornyn
Ted Cruz
Ted Cruz
Representative
Lloyd Doggett
Modified: 8/26/24